ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.

标题
ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 38, Issue 15_suppl, Pages 9513-9513
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2020-05-25
DOI
10.1200/jco.2020.38.15_suppl.9513

向作者/读者发起求助以获取更多资源

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now